¼¼°èÀÇ ºñ¸¸¼¼Æ÷Áõ ÀǾàǰ ½ÃÀå º¸°í¼­(2025³â)
Mastocytosis Drug Global Market Report 2025
»óǰÄÚµå : 1769649
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,324,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,141,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,958,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ºñ¸¸¼¼Æ÷Áõ ÀǾàǰ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµÉ ¿¹Á¤ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¿¹»ó ¼ºÀåÀº Èñ±Í Áúȯ Ä¡·á¿¡ ´ëÇÑ °­Á¶°¡ ³ô¾ÆÁö°í, ¸ÂÃãÇü ÀǾàǰÀÌ µîÀåÇϰí, ¾Ë·¹¸£±â ¹× ¸é¿ª°è ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡Çϰí, º¸Á¶ ¿ä¹ýÀÇ »ç¿ëÀÌ È®´ëµÇ°í, °³¹ß ÁßÀÎ ÀǾàǰÀÇ ÆÄÀÌÇÁ¶óÀÎÀÌ È®´ëµÇ°í Àֱ⠶§¹®À¸·Î º¼ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â°£ µ¿¾È ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ÀÇÇÐ ¿¬±¸ÀÇ Áøº¸, Ç¥Àû Ä¡·á ¿É¼ÇÀÇ °³¹ß, À¯Àü ¿¬±¸ÀÇ ¹ßÀü, º´¿ë ¿ä¹ý Á¢±Ù¹ýÀÇ Ã¤ÅÃ, ¾à¹° Àü´Þ ±â¼úÀÇ Çõ½Å µîÀÌ ÀÖ½À´Ï´Ù.

Èñ±Í Áúȯ¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÇâÈÄ ¸î ³â µ¿¾È ºñ¸¸¼¼Æ÷Áõ ÀǾàǰ ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Èñ±Í ÁúȯÀº Àα¸ÀÇ ¼Ò¼ö, ÀϹÝÀûÀ¸·Î ¹Ì±¹¿¡¼­´Â 20¸¸ ¸í ¹Ì¸¸, À¯·´¿¡¼­´Â 2,000¸í Áß 1¸í ¹Ì¸¸¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÇÇÐÀû »óÅÂÀÔ´Ï´Ù. ÀÌ ºÐ¾ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ÁÖ·Î Èñ±Í ÀǾàǰ ÁöÁ¤, ½ÃÀå µ¶Á¡±Ç ¿¬Àå, ¼¼±Ý °øÁ¦ µî ±ÔÁ¦ Àμ¾Æ¼ºêÀÇ È®´ë¿¡ ±âÀÎÇϸç, ÀÌ·¯ÇÑ Àμ¾Æ¼ºê´Â Á¦¾à ȸ»çÀÇ °³¹ß À§ÇèÀ» ³·Ãß°í ¼öÀͼºÀ» °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ºñ¸¸¼¼Æ÷Áõ Ä¡·áÁ¦´Â ºñ¸¸¼¼Æ÷ÁõÀÇ Áõ»óÀ» °ü¸®ÇÏ´Â µ¥ µµ¿òÀÌ µÉ »Ó¸¸ ¾Æ´Ï¶ó À¯»çÇÑ ¸é¿ª ¶Ç´Â ¼¼Æ÷ °æ·Î¸¦ °øÀ¯ÇÏ´Â ´Ù¸¥ Èñ±Í ÁúȯÀÇ Ä¡·á¹ý ¹ßÀü¿¡µµ ±â¿©Çϴ ǥÀû Ä¡·á¹ýÀ» Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î(2024³â) 4¿ù, ¹Ì±¹¿¡ º»»ç¸¦ µÐ ºñ¿µ¸® ´ÜüÀÎ Global Genes´Â 2024³â 1ºÐ±â¿¡ Èñ±Í Áúȯ ÀǾàǰ °³¹ß¿¡ ÁÖ·ÂÇÏ´Â ±â¾÷µéÀÌ °ø°³ ÁÖ½Ä ¹× 乫 ±ÝÀ¶À» ÅëÇØ 71¾ï ´Þ·¯ÀÇ ÀÚ±ÝÀ» Á¶´ÞÇß´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ´Â 2023³â °°Àº ±â°£¿¡ Á¶´ÞÇÑ 18¾ï ´Þ·¯¿¡ ºñÇØ 307% Áõ°¡ÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ±× °á°ú, Èñ±Í Áúȯ¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡°¡ ºñ¸¸¼¼Æ÷Áõ ÀǾàǰ ½ÃÀåÀÇ È®ÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºñ¸¸¼¼Æ÷Áõ ÀǾàǰ ½ÃÀåÀÇ ¼±µµ ±â¾÷µéÀº Ä¡·á È¿°ú¸¦ ³ôÀ̰í ÁøÇ༺ ºñ¸¸ ¼¼Æ÷ Àå¾Ö ȯÀÚ¸¦ À§ÇÑ Ç¥Àû ¼Ö·ç¼ÇÀ» Á¦°øÇϱâ À§ÇØ Æ¼·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦¿Í °°Àº Çõ½ÅÀûÀÎ Ä¡·á¹ý °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦´Â ºñÁ¤»óÀûÀÎ ¼¼Æ÷ ¼ºÀå¿¡ °ü¿©ÇÏ´Â È¿¼Ò¸¦ Â÷´ÜÇÏ´Â ¾à¹°ÀÔ´Ï´Ù. ºñ¸¸¼¼Æ÷ÁõÀÇ °æ¿ì, ÀÌ·¯ÇÑ ÀǾàǰÀº ºñ¸¸ ¼¼Æ÷ÀÇ °úµµÇÑ ¼ºÀåÀ» ¾ïÁ¦ÇÏ¿© ¹ßÁø ¹× ¿°Áõ°ú °°Àº Áõ»óÀ» ¿ÏÈ­ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 5¿ù, ¹Ì±¹¿¡ º»»ç¸¦ µÐ »ý¸í°øÇÐ ±â¾÷ÀÎ Blueprint Medicines CorporationÀº ¹Ì ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ ISM(indolent systemic mastocytosis, Àú±Þ¼º Àü½Å¼º ºñ¸¸¼¼Æ÷Áõ) ¼ºÀΠȯÀÚ¸¦ Ä¡·áÇϱâ À§ÇÑ Ayvakit(avapritinib)ÀÇ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ ½ÂÀÎÀº ¸¶½ºÆ® ¼¼Æ÷ °ú´Ù »ý»êÀ¸·Î Ư¡Áö¾îÁö´Â Èñ±ÍÇÏ°í ¸¸¼ºÀûÀÎ ÁúȯÀÎ ISM °ü¸®¿¡ ÀÖ¾î Áß¿äÇÑ ÁøÀüÀ» ÀǹÌÇÕ´Ï´Ù. AyvakitÀº ISM ȯÀÚ¿¡°Ô ÈçÈ÷ ¹ß°ßµÇ´Â KIT D816V º¯À̸¦ Ç¥ÀûÇÏ´Â ¼±ÅÃÀû ¾ïÁ¦Á¦·Î, Áõ»ó °ü¸® ¹× Áúȯ °ü¸®¿¡ ÃÊÁ¡À» ¸ÂÃá Ä¡·á ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, Äڷγª 19 ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ª ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦36Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Mastocytosis drugs are medications used to treat mastocytosis, a rare disorder marked by the abnormal buildup of mast cells in the skin, bone marrow, and internal organs. These medications are designed to manage symptoms, suppress mast cell activity, or address more aggressive forms of the condition.

The primary types of mastocytosis drugs include antihistamines, corticosteroids, and mast cell stabilizers. Antihistamines serve as first-line treatments by alleviating symptoms through the prevention of histamine from binding to its receptors during allergic responses. These drugs are used to manage conditions such as systemic mastocytosis, cutaneous mastocytosis, and mast cell activation syndrome. They can be administered orally, intravenously, or subcutaneously. Distribution occurs through hospital pharmacies, online pharmacies, retail stores, and other channels. Key end users include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The mastocytosis drug market research report is one of a series of new reports from The Business Research Company that provides mastocytosis drug market statistics, including the mastocytosis drug industry global market size, regional shares, competitors with the mastocytosis drug market share, detailed mastocytosis drug market segments, market trends, and opportunities, and any further data you may need to thrive in the mastocytosis drug industry. This mastocytosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mastocytosis drug market size has grown strongly in recent years. It will grow from $1.07 billion in 2024 to $1.17 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historic period can be attributed to an aging population, a rising prevalence of blood cancers, increased utilization of biologic and immunotherapies, growing healthcare spending, and a higher incidence of mastocytosis.

The mastocytosis drug market size is expected to see strong growth in the next few years. It will grow to $1.68 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The projected growth during the forecast period can be attributed to a growing emphasis on rare disease treatments, the emergence of personalized medicine, an increasing incidence of allergies and immune system disorders, greater use of supportive therapies, and an expanding pipeline of drugs in development. Key trends anticipated during this period include progress in medical research, the development of targeted treatment options, advancements in genetic research, the adoption of combination therapy approaches, and innovations in drug delivery technologies.

The rising investment in rare diseases is expected to drive the growth of the mastocytosis drug market in the coming years. Rare diseases are medical conditions that impact a small portion of the population-typically fewer than 200,000 individuals in the United States or fewer than 1 in 2,000 people in Europe. Increased investment in this area is largely fueled by growing regulatory incentives such as orphan drug designations, extended market exclusivity, and tax credits, which help lower development risks and improve profitability for pharmaceutical companies. Mastocytosis drugs provide targeted treatment that not only helps manage mastocytosis symptoms but also contributes to the advancement of therapies for other rare diseases sharing similar immune or cellular pathways. For example, in April 2024, Global Genes, a US-based nonprofit organization, reported that in the first quarter of 2024, companies focused on rare disease drug development raised $7.1 billion through public equity and debt financings-a 307% increase compared to the $1.8 billion raised during the same period in 2023. As a result, rising investment in rare diseases is fueling the expansion of the mastocytosis drug market.

Leading companies in the mastocytosis drug market are concentrating on developing innovative treatments such as tyrosine kinase inhibitors to enhance therapeutic effectiveness and offer targeted solutions for patients with advanced mast cell disorders. Tyrosine kinase inhibitors are medications that block enzymes involved in abnormal cell growth. In the context of mastocytosis, these drugs work by inhibiting the excessive growth of mast cells, thereby reducing symptoms like rashes and inflammation. For example, in May 2023, Blueprint Medicines Corporation, a biotechnology company based in the U.S., received approval from the U.S. Food and Drug Administration for Ayvakit (avapritinib) to treat adults with indolent systemic mastocytosis (ISM). This approval represents a significant step forward in managing ISM, a rare and chronic condition marked by the overproduction of mast cells. Ayvakit is a selective inhibitor targeting the KIT D816V mutation, which is commonly found in ISM patients, providing a focused treatment option for symptom control and disease management.

In May 2024, Incyte Corporation, a biopharmaceutical company based in the United States, acquired Escient Pharmaceuticals for approximately $750 million. This acquisition is intended to bolster Incyte's Inflammation and Autoimmunity (IAI) pipeline by incorporating Escient Pharmaceuticals' first-in-class oral MRGPR antagonists, thereby enhancing its ability to develop novel therapies for serious immune and neuro-immune conditions. Escient Pharmaceuticals is a U.S.-based clinical-stage biotechnology company focused on developing EP262, a first-in-class oral MRGPRX2 antagonist aimed at treating mast cell-mediated diseases.

Major players in the mastocytosis drug market are Pfizer Inc., Johnson & Johnson, Bayer AG, Sanofi S.A., Novartis AG, GSK plc, Teva Pharmaceutical Industries Limited, Alcon Inc., Bausch Health Companies Inc., Genentech Inc., Lupin Limited, Blueprint Medicines Corporation, Don Valley Pharma (Pvt.) Ltd., Vivan Life Sciences Private Limited, AB Science S.A., Medoz Pharmaceutical Private Limited, Zumax Biocare Private Limited, Hi-Cure Biotech Private Limited, Zenomed Healthcare Private Limited, Biosynth AG.

North America was the largest region in the mastocytosis drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mastocytosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the mastocytosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mastocytosis drug market also includes sales of antihistamines, leukotriene receptor antagonists, corticosteroids, tyrosine kinase inhibitors (TKIs), and epinephrine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mastocytosis Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mastocytosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for mastocytosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mastocytosis drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Mastocytosis Drug Market Characteristics

3. Mastocytosis Drug Market Trends And Strategies

4. Mastocytosis Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Mastocytosis Drug Growth Analysis And Strategic Analysis Framework

6. Mastocytosis Drug Market Segmentation

7. Mastocytosis Drug Market Regional And Country Analysis

8. Asia-Pacific Mastocytosis Drug Market

9. China Mastocytosis Drug Market

10. India Mastocytosis Drug Market

11. Japan Mastocytosis Drug Market

12. Australia Mastocytosis Drug Market

13. Indonesia Mastocytosis Drug Market

14. South Korea Mastocytosis Drug Market

15. Western Europe Mastocytosis Drug Market

16. UK Mastocytosis Drug Market

17. Germany Mastocytosis Drug Market

18. France Mastocytosis Drug Market

19. Italy Mastocytosis Drug Market

20. Spain Mastocytosis Drug Market

21. Eastern Europe Mastocytosis Drug Market

22. Russia Mastocytosis Drug Market

23. North America Mastocytosis Drug Market

24. USA Mastocytosis Drug Market

25. Canada Mastocytosis Drug Market

26. South America Mastocytosis Drug Market

27. Brazil Mastocytosis Drug Market

28. Middle East Mastocytosis Drug Market

29. Africa Mastocytosis Drug Market

30. Mastocytosis Drug Market Competitive Landscape And Company Profiles

31. Mastocytosis Drug Market Other Major And Innovative Companies

32. Global Mastocytosis Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Mastocytosis Drug Market

34. Recent Developments In The Mastocytosis Drug Market

35. Mastocytosis Drug Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â